Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy

Basit Öğe Kaydı
dc.contributor.authorEbinc, Senar
dc.contributor.authorOruc, Zeynep
dc.contributor.authorSezgin, Yasin
dc.contributor.authorKarhan, Ogur
dc.contributor.authorBilen, Erkan
dc.contributor.authorYerlikaya, Halis
dc.contributor.authorKalkan, Ziya
dc.date.accessioned2024-04-24T17:18:40Z
dc.date.available2024-04-24T17:18:40Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractPlain language summary HER2 is an important and targetable molecule in breast cancer. In the early stages of breast cancer, a treatment modality called neoadjuvant therapy, which now includes anti-HER2 therapies, is administered before surgery in order to achieve disease regression and make the patient suitable for a more minor operation. In breast cancer, HER2 status may be positive in the initial biopsy specimen and negative in the surgical specimen. HER2 status plays an important role in treatment decisions. In this study, we investigated the factors causing HER2 status to change in early-stage breast cancer. This study has a retrospective design and includes 400 female patients with early-stage breast cancer. The results of the study identified the factors causing HER2 status to change to negative as receipt of neoadjuvant therapy, small tumor size and younger age. Objective: The rates of and the factors influencing HER2 discordance in patients receiving neoadjuvant therapy for breast cancer are investigated. Methods: This study retrospectively examines the rates of HER2 and hormone receptor discordance between the biopsy and postoperative resection specimens of 400 female early-stage breast cancer patients. Results: One hundred and thirty-three (33.3%) patients had received neoadjuvant therapy. The rate of HER2 discordance between biopsy and resection specimens was 1.7% in the control group and 5.3% in the neoadjuvant therapy group (p = 0.018). The rate of HER2 discordance was higher in younger patients and in patients with T1 tumors in the neoadjuvant therapy group. Conclusion: Neoadjuvant therapy, age <40 years and smaller tumor size were independent risk factors for HER2 discordance.en_US
dc.identifier.doi10.2217/fon-2022-0198
dc.identifier.endpage3408en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue30en_US
dc.identifier.pmid36069377
dc.identifier.scopus2-s2.0-85141889188
dc.identifier.scopusqualityQ2
dc.identifier.startpage3399en_US
dc.identifier.urihttps://doi.org/10.2217/fon-2022-0198
dc.identifier.urihttps://hdl.handle.net/11468/18867
dc.identifier.volume18en_US
dc.identifier.wosWOS:000850491800001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofFuture Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiopsyen_US
dc.subjectBreast Canceren_US
dc.subjectChemotherapyen_US
dc.subjectDiscordanceen_US
dc.subjectEstrogen Receptoren_US
dc.subjectHer2en_US
dc.subjectNeoadjuvant Therapyen_US
dc.subjectProgesterone Receptoren_US
dc.subjectReceptoren_US
dc.subjectRisk Factorsen_US
dc.titleFactors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapyen_US
dc.titleFactors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu